Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, focusing on a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [5] Offering Details - The company closed a registered direct offering with Janus Henderson Investors for 20,000,000 shares of common stock at a price of $1.00 per share, along with warrants to purchase an additional 20,000,000 shares at an exercise price of $1.50 per share [1][3] - The gross proceeds from the offering were approximately $20 million, which is expected to extend the company's cash runway into the second quarter of 2026 [3] - If the warrants are fully exercised, the company could receive up to an additional $30 million, potentially extending the cash runway into the first quarter of 2027 [3] Financial Advisors - Noble Capital Markets, Inc. acted as the sole placement agent for the offering, while Maxim Group LLC and Titan Partners Group served as independent financial advisors [2]